Overview

A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

Status:
Completed

Trial end date:
2015-10-01

Target enrollment:

Participant gender:

Summary

This is a 6-month, open-label, flexible-dose study evaluating desvenlafaxine succinate sustained release (DVS SR) in the treatment of child and adolescent outpatients with major depressive disorder (MDD).

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Desvenlafaxine Succinate